FP7 Sadel Project
Since January 2012, ECCO is a Consortium Partner in the EU FP7 Sadel Project in which research efforts focus on Scaffolds for Alternative DELivery and Nanofitin®-based drug in Inflammatory Bowel Disease (IBD):
- Small size (optimal tissue penetration)
- Resistance to pH and to human intestinal fluids (long-half-life in digestive track)
- High affinity (low effective concentration needed)
- Strong potential for reduced immunogenicity compared to current biologic
Oral Presentation at ECCO'15: Oral delivery of a new class of non-antibody protein scaffold nanofitins targeting TNF-alpha shows a strong preventive and curative anti-inflammatory effect in models of Inflammatory Bowel Diseases
Source: e-CCO Learning Webcast - ECCO 2015 Barcelona Congress - Scientific session 11: Managing the manageable: Chronic pain and fatigue
Authors: Mathieu Cinier
Oral Presentation at the EU Project Forum, ECCO'16: SADEL Project - Scaffolds for Alternative Delivery
ECCO FP7 Sadel Officer
Andreas Sturm
Department of Gastroenterology
DRK Kliniken Berlin | Westend
Berlin, Germany
This email address is being protected from spambots. You need JavaScript enabled to view it.
ECCO FP7 Sadel Research Fellow
Raja Atreya
Medizinische Klinik 1
Universitätsklinikum Erlangen
Erlangen, Germany
This email address is being protected from spambots. You need JavaScript enabled to view it.